EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...
Moderna said on Friday that the U.S. FDA paused a late-stage trial of its experimental norovirus vaccine after a case of a ...
Barclays downgraded shares of Moderna (NASDAQ:MRNA – Free Report) from an overweight rating to an equal weight rating in a report published on Tuesday, Ratings reports. The firm currently has $45.00 ...
BofA analyst Tim Anderson lowered the firm’s price target on Moderna (MRNA) to $32 from $34 and keeps an Underperform rating on the shares.
Moderna Inc. recorded another quarterly loss as vaccine sales wane and the company had an unexpected charge for a canceled ...
Biotech firm Moderna reported a bigger-than-expected quarterly loss on Friday, hit by a charge related to its efforts to ...
Barclays downgraded Moderna (MRNA) to Equal Weight from Overweight with a price target of $45, down from $111, post the Q4 report. The firm ...
A trial of Moderna’s norovirus vaccine in the U.S. has been put on hold by the FDA over a reported case of neurological ...
It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the ...
Moderna is revamping its digital team, eliminating 10% of roles under two digital departments, affecting about 50 employees, ...
An image that is spreading widely online claims that Moderna had created its COVID-19 vaccine two years before the pandemic ...